Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Randomized Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Three Doses of Frevecitinib (KN-002) in Patients With Severe Asthma

NCT07532265 is registered in ClinicalTrials.gov with Kinaset Therapeutics Inc as lead sponsor.

NCT NCT07532265
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07532265 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Randomized Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Three Doses of Frevecitinib (KN-002) in Patients With Severe Asthma
Lead sponsor
Kinaset Therapeutics Inc
Phase
Phase 2
Overall status
Recruiting
Start date
July 16, 2026
Completion date
November 30, 2027
Enrollment
512 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

severe asthma